Skip to main content

Day: May 27, 2020

Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., and WASHINGTON, May 27, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2020 ALS Roundtables and ALS Focus, a patient and caregiver led survey program to learn about individual experiences with ALS. Cytokinetics is also a Platinum Level Sponsor for initiatives led by The ALS Association Golden West Chapter, including grant funding for care services for people with ALS in the Bay Area. “We are proud to continue our longstanding partnership with The ALS Association and The ALS Association Golden West Chapter,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “During these especially difficult times, people with ALS and their families...

Continue reading

Zai Lab Announces Presentations at June Conferences

Written by Customer Service on . Posted in Public Companies.

SHANGHAI and SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) — Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that the Company will be presenting at the following upcoming virtual conferences in June. Details of the virtual conferences are as follows:Jefferies Global Healthcare Conference 2020Presentation: Tuesday, June 2, 2020 at 3:00 p.m. EDTPresenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive OfficerGoldman Sachs 41st Annual Global Healthcare ConferencePresentation: Thursday, June 11, 2020 at 9:40 a.m. EDTPresenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive OfficerJP Morgan China Investor ConferencePanel Discussion: Wednesday, June 24, 2020 at 8:00 a.m. CSTPresenter: Dr. Samantha Du, Founder, Chairperson & Chief Executive...

Continue reading

Canadian Metals Project Update: Seeks Opportunities into CO2 Capture and Neutralization Industry Sector

Written by Customer Service on . Posted in Public Companies.

MONTREAL, May 27, 2020 (GLOBE NEWSWIRE) — Canadian Metals Inc. (“CME” or the “Company”) (CSE: CME) announced a management and project review on April 24, 2020 for its silicon metal project. Silicon metal’s main applications are in the energy saving sector such as photovoltaic applications and play an important role in the global energy transformation.The production of silicon metal requires significant amounts of electricity and Quebec has the great advantage of green hydro power and the wood industry to provide renewable sources for woodchips used in the process. Unfortunately, the process still requires coal as an irreplaceable input material. Therefore, we have set ourselves the goal of fully compensating the gas emissions from coal.We want to combine the future silicon metal plant with a CO2 neutralization solution with the...

Continue reading

vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions

Written by Customer Service on . Posted in Public Companies.

HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th Scientific Sessions, which is being held virtually, June 12–16, 2020.In February 2020 the Company announced positive topline results from its Phase 2 (Part 2) Simplici-T1 trial showing that TTP399 lowered HbA1c, decreased insulin dose, and increased Time in Range in patients with type 1 diabetes (T1D).Details of the virtual presentations which will provide full clinical study data from that trial follow:Late-Breaking Poster Title: “The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes”Poster...

Continue reading

MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia

Written by Customer Service on . Posted in Public Companies.

Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study intended to support registration in the U.S. of flotetuzumab, an investigational, bispecific CD123 x CD3 DART® molecule for patients with acute myeloid leukemia (AML) who are refractory to induction therapy.Informed by recent discussions with the U.S. Food and Drug Administration (FDA), the Company plans a single-arm, registration-enabling clinical study to evaluate flotetuzumab in up to 200 patients with primary induction failure (PIF) or early relapse (ER) AML. The study will be conducted as a continuation of the ongoing Phase 1/2 study (NCT02152956;...

Continue reading

Periodemeddelelse 31. marts 2020

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Lollands Bank offentliggør perioderegnskabet for 1. kvartal 2020.Kvartalets hovedoverskrifter er følgende:Basisindtjeningen øges med 2,5 mio. kr. i forhold til samme periode i 2019.Bankens nedskrivninger udgør i første kvartal af 2020 en udgift på 1,2 mio. kr. mod samme periode sidste år 5,1 mio. kr.Banken har i perioden 1. januar til 31. marts 2020 opnået et resultat før skat på 5,5 mio. kr. og efter skat 4,0 mio. kr. mod samme periode forrige år 20,3 mio. kr. før skat og 16,1 mio. kr. efter skat. Forskellen kan primært henføres til negative kursreguleringer i dette år grundet COVID-19 pandemien.Vedhæftet filPeriodemeddelelse 1. kvt 2020

Continue reading

GobiMin Announces First Quarter 2020 Results 

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

TORONTO, May 27, 2020 (GLOBE NEWSWIRE) — (TSXV: GMN) GobiMin Inc. (“GobiMin” or the “Company”, together with its subsidiaries collectively the “Group”) reports its financial and operating results for the first quarter of 2020. The unaudited condensed interim financial statements along with quarterly highlights of management’s discussion and analysis have been filed with SEDAR (www.sedar.com) and are also available at the website of the Company (www.gobimin.com). Financial HighlightsNote:As non-IFRS measurements, (LBITDA)/EBITDA ((loss)/earnings before interest income and expense, income taxes, depreciation and amortization), (LBITDA)/EBITDA per share and Cash and cash equivalents per share do not comply with IFRS and, therefore, the amounts presented in the above table may not be comparable to similar data presented by other companies....

Continue reading

Ascot Resources Announces C$25 Million Bought Deal Financing

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, May 27, 2020 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF)  (“Ascot” or the “Company”) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by Desjardins Capital Markets and Stifel GMP, pursuant to which the Underwriters have agreed to purchase, on a bought‐deal basis, 29,412,000 common shares of the Company (“Shares”) at a price of C$0.85 per Share for aggregate gross proceeds to the Company of C$25.0 million (the “Offering”).The Underwriters have been granted an option (the “Over‐Allotment Option”), exercisable in whole or in part, at any time within 30 days following the closing of the Offering, to purchase from the Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.